Picture [iito] No Tracking 650x80px
Document › Details

Arcis Biotechnology Ltd.. (10/16/18). "Press Release: Arcis Biotechnology and Teleflex Sign License Agreement". Daresbury.

Organisations Organisation Arcis Biotechnology Ltd.
  Group Arcis:Altos (Group)
  Organisation 2 Teleflex Inc. (NYSE: TFX)
  Group Teleflex (Group)
Products Product nucleic acid extraction (technology)
  Product 2 sample preparation (technology)
Index term Index term Teleflex–Arcis:Altos: nucleic acid sample preparation technology, 201810– license to Teleflex from Arcis Biotechnology
Persons Person Whitehurst, Peter (Arcis:Altos 201810 CEO of Arcis Biotechnology)
  Person 2 Odgaard, Katie (Zyme Communications 201108 Senior Account Manager before College Hill Life Sciences)

Agreement gives Teleflex access to Arcis’ nucleic acid sample preparation technology

Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has signed a technology access agreement with Teleflex Incorporated, a New York Stock Exchange listed company (NYSE: TFX). Teleflex will harness Arcis’ advanced nucleic acid sample preparation chemistry in the development of a novel technology, which it believes will be disruptive, and is intended to empower clinicians and drive better patient outcomes.

Arcis’ product portfolio offers the possibility of earlier, more accurate diagnostics testing from a variety of sample types, using its rapid, two-step nucleic acid extraction and preservation technology. The company has an extensive patent portfolio covering DNA and RNA extraction and preservation for downstream processing by qPCR, RT-qPCR and sequencing in under three minutes. The speed, simplicity and low-resource requirements of the platform provides an ideal solution for point-of-care, microfluidics or field-based testing, and supports both companies’ drive to improve diagnostic testing and benefit patients and healthcare professionals.

Peter Whitehurst, CEO, Arcis Biotechnology, commented: “We are delighted that Teleflex has chosen to leverage the speed and simplicity of our sample preparation technology in its product development programme. Obtaining genetic material from biological samples is a critical step in molecular biology processes, and we are excited to see our platform being applied across many different and growing markets.”

This news follows the announcement of a successful £1.25 million investment round and additional £0.5 million overfunding hosted by crowdfunding platform Capital Cell. Following Arcis’ recent development successes in the isolation and preservation of microRNA (miRNA) and oncology biomarkers, Arcis is now looking to invest further in R&D, product development, and to drive international business expansion. The additional £0.5 million from the Capital Cell funding round will underpin the Company’s projected revenue growth and associated working capital requirements in the next two years.

Details of the Arcis Biotechnology investment round can be found here:


Notes to editors

Media contact:

Katie Odgaard
Zyme Communications
Tel: +44(0) 7787 502 947

About Arcis Biotechnology (

Based at Sci-Tech Daresbury, one of the UK’s premier science parks, Arcis Biotechnology is focused on providing fast and convenient nucleic acid sample prep solutions. Obtaining genetic material from biological samples is a critical step which is often a time consuming and inefficient process. In less than three minutes, and with no prior sample preparation, the Arcis Sample Prep range of products allow users to quickly and conveniently go from cellular material to downstream nucleic acid investigation without the need for traditional isolation or purification. The process requires no laboratory equipment, and as little as 30µl of sample as starting material.

The Arcis technology, including two CE marked in vitro diagnostic products, can be used on many different samples containing DNA and RNA, including whole blood, plasma, urine, buccal swabs, and soil and plant extracts, and is particularly effective at isolating pathogens for detection.

About Teleflex Incorporated (

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® - trusted brands united by a common sense of purpose.

Record changed: 2018-10-24


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Arcis:Altos (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

» top